Weight Loss and Vitality
Weight Loss and Vitality · 5904 Richmond Hwy Suite 350 · Manassas, VA 20109
5.0· 50 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
- Endocrine / metabolic care
About this practice
In Manassas, Virginia, Weight Loss and Vitality is one of several locations of a practice whose website describes team-based care built on evidence-based medicine, individualized treatment plans and ongoing support. The site names clinicians including David Bauder, PA-C, and Christopher Reeves, MD, and the listing for this office includes semaglutide, tirzepatide and hormone care. The Manassas office has a 5.0-star Google rating across 50 reviews dating to 2022, with 4 in the past year, and reviewers most often point to the providers' knowledge, then the staff and results.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Yes |
| Telehealth visits | Not listed |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-06. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 50 Google reviews. Of the 50 reviews we analyzed, 50 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Knowledgeable, professional providers17 reviews
- Friendly, helpful staff10 reviews
- Weight-loss results8 reviews
- Feeling listened to5 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Ann C.★★★★★2026-06-11Love dr Bauder. He is so helpful and knowledgeable. He takes time to answer any questions and he is truly a pleasure to deal with. I even look forward to my appointments with him. Thank you!!
johnny s.★★★★★2025-10-10Dr Bauder is always thorough, informative and professional and always feel comfortable talking with him
Geraldine T.★★★★★2025-05-02David Bauder is extremely knowledgeable and has a gift for breaking down how the body processes intake and its relationship to losing weight. This practice is highly reputable and their one-on-one approach with clients is exemplary
Christine C.★★★★★2025-03-05I enjoy my visits every time. It is worth the drive to travel over an hour to get there. The staff is warm and welcoming and the visit is never rushed. I recommend this practice to everyone!
Scott K.★★★★★2024-12-03Very professional and friendly staff
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs